Evidence map›Paper›PMID 40887130›Full record

ReviewBMJ open2025

Design aspects for prognostic factor studies.

Peggy Sekula, Inga Steinbrenner, Ulla T Schultheiss, Neus Valveny, Paola Rebora, Susan Halabi, Suzanne M Cadarette, Richard D Riley, Gary S Collins, Willi Sauerbrei and 2 more

Abstract readReview
In one paragraph

Review in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Independent Prognostic Factors for Predicting Wound Healing in People With Venous Leg Ulcers: A Systematic Review and Meta-Analysis.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society
    Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Peggy SekulaInstitute of Genetic Epidemiology, Faculty of Medicine and Medical Center - University of Freiburg, Freiburg, Germany peggy.sekula@uniklinik-freiburg.de.ORCID http://orcid.org/0000-0003-2263-447X
Inga SteinbrennerInstitute of Genetic Epidemiology, Faculty of Medicine and Medical Center - University of Freiburg, Freiburg, Germany.ORCID http://orcid.org/0000-0003-0851-5773
Ulla T SchultheissInstitute of Genetic Epidemiology, Faculty of Medicine and Medical Center - University of Freiburg, Freiburg, Germany.
Neus ValvenyReal World Evidence, TFS HealthScience, Barcelona, Spain.
Paola ReboraBicocca Bioinformatics, Biostatistics and Bioimaging Centre - B4, School of Medicine and Surgery, University of Milan-Bicocca, Milano, Italy.
Susan HalabiDepartment of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina, USA.ORCID http://orcid.org/0000-0003-4135-2777
Suzanne M CadaretteLeslie Dan Faculty of Pharmacy & Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
Richard D RileySchool of Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK.ORCID http://orcid.org/0000-0001-8699-0735
Gary S CollinsCentre for Statistics in Medicine, UK EQUATOR Centre, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-2772-2316
Willi SauerbreiInstitute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center - University of Freiburg, Freiburg, Germany.
Mitchell H GailBiostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.ORCID http://orcid.org/0000-0002-3919-3263
for topic group 5 of the STRATOS initiative

Funding

Clinical genomic predictive model of first line androgen receptor inhibitor therapy outcomes in men with mCRPCR01CA256157 · NCI · DUKE UNIVERSITY · PI ARMSTRONG, ANDREW J, DEHM, SCOTT M. · 2020 to 2025
$3.2M
Benefits and Harms of Long-term Osteoporosis Pharmacotherapy: Impact of Treatment Length, Type, Switching, and HolidaysR01AG078759 · NIA · BROWN UNIVERSITY · PI CADARETTE, SUZANNE, HAYES, KALEEN NICOLE · 2022 to 2025
$2.5M
Interactions of Androgen Production, Uptake and Metabolism on outcome in Castration Resistant Prostate CancerR01CA249279 · NCI · UNIVERSITY OF MINNESOTA · PI HALABI, SUSAN, SHARIFI, NIMA · 2021 to 2024
$2.1M
FDA HHS U01 FD007857NCI NIH HHS R01 CA249279NCI NIH HHS R01 CA256157NIA NIH HHS R01 AG078759
6 · The paper itself

Abstract

Prognostic research is clinically relevant and ultimately facilitates stratified medicine. However, its quality and output are limited. More guidance is needed to improve understanding and thus quality. On behalf of the topic group 'TG5: study design' of the STRATOS initiative and for the general readership, this article describes key concepts and issues for prognostic factor studies, a sub-area of prognosis research. After providing a general overview on prognosis research, the article covers aspects such as aims, estimands and designs of prognostic factor studies, highlighting standards and current practice. Focusing on prognostic factor studies that assess a single factor at a time and a binary outcome, this article is complemented by a glossary of terms and a list of general aspects to consider in prognostic factor studies.

Indexed as

Biomedical ResearchResearch DesignHumansPrognosisEPIDEMIOLOGIC STUDIESEPIDEMIOLOGYPrognosisResearch DesignSTATISTICS & RESEARCH METHODS

Identifiers

PMID40887130
PMCPMC12406931

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.